Ciproterona acetato (Esperanto Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ciproterona acetato" in Esperanto language version.

refsWebsite

Global rank Esperanto rank

3^rd place

6^th place

2^nd place

7^th place

low place

399^th place

1,384^th place

books.google.com

J. Elks. (14-a de novembro 2014) The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer, p. 339–. ISBN 978-1-4757-2085-3.
(2007) Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. World Health Organization. ISBN 978-92-832-1291-1.
Jonathan S. Berek. (2007) Berek & Novak's Gynecology. Lippincott Williams & Wilkins. ISBN 978-0-7817-6805-4.
Georg F. Weber. (22-a de julio 2015) Molecular Therapies of Cancer. Springer, p. 316–. ISBN 978-3-319-13278-5. “The terminal half-life is about 38 h. A portion of the drug is metabolized by hydrolysis to cyproterone and acetic acid. However, in contrast to many other steroid esters hydrolysis is not extensive, and much of the pharmacological activity is exerted by the acetate form. Excretion is about 70% in the feces, mainly in the form of glucuronidated metabolites, and about 30% in the urine, predominantly as non-conjugated metabolites.”.
Sarah H. Wakelin. (1-a de junio 2002) Systemic Drug Treatment in Dermatology: A Handbook. CRC Press. ISBN 978-1-84076-013-2.
(January 2000) Index Nominum 2000: International Drug Directory. Taylor & Francis, p. 289–. ISBN 978-3-88763-075-1.
Loren S Schechter. (22-a de septembro 2016) Surgical Management of the Transgender Patient. Elsevier Health Sciences, p. 26–. ISBN 978-0-323-48408-4.

(1998) AAPL Newsletter. The Academy. “CPA is 100% bioavailable when taken orally with a half life of 38 hours. The injectable form reaches maximum plasma levels in 82 hours and has a half life of about 72 hours.”.

(November 1986) “Pharmacology of antiandrogens”, Journal of Steroid Biochemistry 25 (5B), p. 885–95. doi:10.1016/0022-4731(86)90320-1.
(2000) “Androgen Receptor Antagonists (Antiandrogens) Structure-Activity Relationships”, Current Medicinal Chemistry 7 (2), p. 211–247. doi:10.2174/0929867003375371.